BR112017013286A2 - composto de isoxazolina, e, uso de um composto de isoxazolina. - Google Patents

composto de isoxazolina, e, uso de um composto de isoxazolina.

Info

Publication number
BR112017013286A2
BR112017013286A2 BR112017013286-9A BR112017013286A BR112017013286A2 BR 112017013286 A2 BR112017013286 A2 BR 112017013286A2 BR 112017013286 A BR112017013286 A BR 112017013286A BR 112017013286 A2 BR112017013286 A2 BR 112017013286A2
Authority
BR
Brazil
Prior art keywords
isoxazoline compound
isoxazoline
compound
administering
formula
Prior art date
Application number
BR112017013286-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Williams Heike
Regina Heckeroth Anja
Tänzler Janina
Joël Alain Frenais Régis
Original Assignee
Intervet International B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52146273&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017013286(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intervet International B.V. filed Critical Intervet International B.V.
Publication of BR112017013286A2 publication Critical patent/BR112017013286A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/14Ectoparasiticides, e.g. scabicides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
BR112017013286-9A 2014-12-22 2015-12-21 composto de isoxazolina, e, uso de um composto de isoxazolina. BR112017013286A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14199562 2014-12-22
EP14199562.1 2014-12-22
PCT/EP2015/080744 WO2016102437A1 (en) 2014-12-22 2015-12-21 Use of isoxazoline compounds for treating demodicosis

Publications (1)

Publication Number Publication Date
BR112017013286A2 true BR112017013286A2 (pt) 2018-03-06

Family

ID=52146273

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017013286-9A BR112017013286A2 (pt) 2014-12-22 2015-12-21 composto de isoxazolina, e, uso de um composto de isoxazolina.

Country Status (14)

Country Link
US (3) US20170348286A1 (https=)
EP (3) EP3236960B1 (https=)
JP (1) JP6706262B2 (https=)
CN (2) CN106999475B (https=)
AU (3) AU2015371175B2 (https=)
BR (1) BR112017013286A2 (https=)
CA (1) CA2971296A1 (https=)
DK (2) DK4008329T3 (https=)
ES (2) ES3037078T3 (https=)
FI (2) FI3236960T3 (https=)
PL (2) PL3236960T3 (https=)
PT (2) PT4008329T (https=)
RU (1) RU2709198C2 (https=)
WO (1) WO2016102437A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170232024A1 (en) 2014-08-04 2017-08-17 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
EP3236960B1 (en) 2014-12-22 2025-01-29 Intervet International B.V. Fluralaner for use in the treatment of demodicosis
WO2018039508A1 (en) * 2016-08-25 2018-03-01 Merial, Inc. Method for reducing unwanted effects in parasiticidal treatments
CN107501199A (zh) * 2017-08-16 2017-12-22 南京农业大学 氟雷拉纳单体化合物的提取和纯化方法
WO2019118928A1 (en) * 2017-12-15 2019-06-20 Tarsus Pharmaceuticals, Inc. Isoxazoline parasiticide formulations and methods for treating blepharitis
US12502377B2 (en) 2019-04-04 2025-12-23 Tarsus Pharmaceuticals, Inc. Method of eradicating ticks that attach to humans using lotilaner formulations
US11880349B2 (en) 2019-04-30 2024-01-23 Salesforce, Inc. System or method to query or search a metadata driven distributed ledger or blockchain
EP4077286A1 (en) 2019-12-18 2022-10-26 Elanco Tiergesundheit AG Isoxazoline derivatives as pesticides
KR20230043904A (ko) 2020-07-24 2023-03-31 엘랑코 유에스 인코포레이티드 이속사졸린 화합물 및 이의 중간체의 제조 공정
CN116744917A (zh) 2020-09-04 2023-09-12 礼蓝美国公司 适口调配物
CN115785017B (zh) * 2022-12-06 2023-12-08 海利尔药业集团股份有限公司 一种取代的苯酰胺异噁唑啉衍生物或其作为农药可接受的盐、组合物及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2067863C1 (ru) * 1994-05-25 1996-10-20 Казанский государственный технологический университет Акарицидный состав для лечения чесотки домашних животных
CN101768129B (zh) 2004-03-05 2012-05-23 日产化学工业株式会社 异*唑啉取代苯甲酰胺化合物的制备中间体
DE102004053964A1 (de) * 2004-11-09 2006-05-11 Bayer Healthcare Ag Mittel gegen Demodikose
TWI412322B (zh) 2005-12-30 2013-10-21 Du Pont 控制無脊椎害蟲之異唑啉
TWI430995B (zh) 2007-06-26 2014-03-21 Du Pont 萘異唑啉無脊椎有害動物控制劑
KR101769728B1 (ko) 2007-06-27 2017-08-18 이 아이 듀폰 디 네모아 앤드 캄파니 동물 해충 방제 방법
TWI556741B (zh) * 2007-08-17 2016-11-11 英特威特國際股份有限公司 異唑啉組成物及其作為抗寄生蟲藥上的應用
TWI411395B (zh) 2007-12-24 2013-10-11 Syngenta Participations Ag 殺蟲化合物
US8377942B2 (en) 2008-12-18 2013-02-19 Novartis Ag Isoxazolines derivatives and their use as pesticide
HUE015568T4 (en) 2008-12-19 2017-10-30 Elanco Tiergesundheit Ag Isoxazoline derivatives and their use as pesticides
NZ611474A (en) 2010-12-27 2015-08-28 Intervet Int Bv Topical localized isoxazoline formulation comprising glycofurol
JP6002148B2 (ja) 2010-12-27 2016-10-05 インターベット インターナショナル ベー. フェー. 経表面局所イソオキサゾリン製剤
ME02412B (me) * 2011-03-10 2016-09-20 Zoetis Services Llc Spirociklični derivati izoksazolina kao antiparazitska sredstva
RS58417B1 (sr) 2011-09-12 2019-04-30 Merial Inc Paraziticidne kompozicije koje sadrže izoksazolinsko aktivno sredstvo, postupci i upotrebe povezane sa njima
EP3216448B8 (en) * 2012-02-06 2019-06-05 Boehringer Ingelheim Animal Health USA Inc. Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
WO2013150055A1 (en) 2012-04-04 2013-10-10 Intervet International B.V. Solid oral pharmaceutical compositions for isoxazoline compounds
WO2014090918A1 (en) * 2012-12-13 2014-06-19 Novartis Ag Process for the enantiomeric enrichment of diaryloxazoline derivatives
EP3082867B1 (en) * 2013-12-20 2024-01-17 Intervet International B.V. Isoxazoline compositions and use thereof in the prevention or treatment of parasite infestations in animals
EP3236960B1 (en) 2014-12-22 2025-01-29 Intervet International B.V. Fluralaner for use in the treatment of demodicosis

Also Published As

Publication number Publication date
AU2023219972A1 (en) 2023-09-14
CN114681453A (zh) 2022-07-01
ES3037078T3 (en) 2025-09-26
US20200405692A1 (en) 2020-12-31
FI3236960T3 (fi) 2025-04-05
EP4008329B1 (en) 2025-06-11
EP4599830A2 (en) 2025-08-13
AU2015371175B2 (en) 2021-03-04
DK4008329T3 (da) 2025-08-18
JP6706262B2 (ja) 2020-06-03
EP3236960B1 (en) 2025-01-29
WO2016102437A1 (en) 2016-06-30
RU2017126029A (ru) 2019-01-24
PL4008329T3 (pl) 2025-11-17
DK3236960T3 (da) 2025-03-31
ES3018234T3 (en) 2025-05-14
PT3236960T (pt) 2025-04-08
CN106999475A (zh) 2017-08-01
US20170348286A1 (en) 2017-12-07
AU2023219972B2 (en) 2025-05-29
PL3236960T3 (pl) 2025-07-07
RU2709198C2 (ru) 2019-12-17
CA2971296A1 (en) 2016-06-30
AU2021203686A1 (en) 2021-07-01
EP4599830A3 (en) 2025-11-19
PT4008329T (pt) 2025-07-30
EP3236960A1 (en) 2017-11-01
CN106999475B (zh) 2022-10-25
RU2017126029A3 (https=) 2019-06-20
US10799483B2 (en) 2020-10-13
US20180318265A1 (en) 2018-11-08
AU2015371175A1 (en) 2017-06-15
EP4008329A1 (en) 2022-06-08
JP2017538767A (ja) 2017-12-28
FI4008329T3 (fi) 2025-08-22

Similar Documents

Publication Publication Date Title
BR112017013286A2 (pt) composto de isoxazolina, e, uso de um composto de isoxazolina.
EA201692219A1 (ru) Способы получения противовирусных соединений
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
BR112016019871A2 (pt) anticorpos anti-cd38 para o tratamento de leucemia linfoblástica aguda
BR112017005266A2 (pt) inibidores de mk2 e uso dos mesmos
BR112016014020A8 (pt) moduladores de tetra-hidropiridopirazinas de gpr6.
EA201692338A1 (ru) Соединения 5-хлор-дифторметоксифенил-пиразолопиримидина, представляющие собой ингибиторы янус-киназы
EA201790266A1 (ru) Индолы для применения при инфекции, вызванной вирусом гриппа
CL2016001349A1 (es) Uso de derivados de bencimidazol-prolina
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
GT201600066A (es) Composiciones y métodos para inhibir la expresión del gen alas1
BR112017008176A2 (pt) método de preparação do carbonato de ácido glicérico.
BR112017002662A2 (pt) processo para preparar furfural e/ou derivados de furfural.
EA201691412A1 (ru) Гидроксиформамидные производные и их применение
MX2015010728A (es) Metodos y composiciones para el tratamiento de leucemia.
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
BR112017014416A2 (pt) sal de mangiferina-6-o-berberina e método de preparação e uso do mesmo
DOP2016000211A (es) Pirazinas moduladoras de gpr6
MX384794B (es) Proceso para la preparacion de 5-fluoro-1h-pirazoles a partir de hexafluoropropeno.
MX373636B (es) Compuestos de azetidiniloxifenilpirrolidina.
CL2017000151A1 (es) Derivados de piridona
BR112017009854A2 (pt) composto, uso de um composto, e, método para tratamento de leucemia.
BR112018006005A2 (pt) composto bicíclico e uso do mesmo para inibição de suv39h2
BR112016027455A2 (pt) moduladores ppar
BR112017025264A2 (pt) tratamento de prurido

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122022022387-7 PROTOCOLO 870220101799 EM 03/11/2022 19:17.

B12B Appeal against refusal [chapter 12.2 patent gazette]